RT Journal Article
SR Electronic
T1 The role of incentives in deciding to receive the available COVID-19 vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.11.21261829
DO 10.1101/2021.08.11.21261829
A1 Shmueli, Liora
YR 2021
UL http://medrxiv.org/content/early/2021/08/13/2021.08.11.21261829.abstract
AB Objective To assess the public’s intention to get vaccinated immediately after COVID-19 vaccine became available, and to determine the role of incentives beyond socio-demographic, health-related and behavioral factors, in predicting this intention.Methods An online survey was conducted among adults in Israel (n=461), immediately after the first COVID-19 vaccine became available (22/12/2020 to 10/1/2021). Two regressions were performed to investigate determinants of intention and sense of urgency to receive the available COVID-19 vaccine.Results Although many adults intended to receive available COVID-19 vaccine, only 65% intended to immediately receive the vaccine; 16% preferred to wait 3 months and 18% preferred to wait a year. The sense of urgency to get vaccinated differed by age, periphery-level, perceived barriers, cues to action and availability. Monetary rewards or the “green pass” incentives didn’t increase the probability of getting vaccination immediately.Conclusions Providing data on the role of incentives in increasing the intention to immediately receive the available COVID-19 vaccine is important for health policy makers and healthcare providers. Our findings underscore the importance of COVID-19 vaccine accessibility.Practice Implications Health policy makers should consider allocating funds for making the vaccine accessible and encourage methods of persuasion, instead of investing funds in monetary incentives.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNot applicableAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee for Non-clinical Studies at Bar-Ilan University in Israel. The ethics form was signed by the committee head on December 20, 2020.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesxI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during the current study are not publicly available but are available from the corresponding author on reasonable request.HBMHealth Belief ModelWHOWorld Health OrganizationEULsEmergency Use Listing